Trial 11S-17-1


PhII-148 A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Alveolar Soft Part Sarcoma

Type: Treatment
Phase: Phase II
Status: Closed to Accrual with Ongoing Follow-up
Treatments: Biological Response Modifier
Randomized: No
USC Satellite Location: USC Newport Beach Oncology
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  James Hu, M.D.
Other Trial Staff:  Fahim Raian, D.M., Victoria Amran, D.M., Jiayi Jiang, D.M., Mary Ordaz, D.M., Gina Tse, Coordinator, Kristy Sartor Massopust, Coordinator, Noureddine Miloud, D.M., Shamim Jhimlee, Coordinator, Eduardo Mejia, D.M., Yanli Wang, D.M., Laurie De Oliveira, Coordinator, Niranjan Bhatt, D.M., Kristy Watkins, Coordinator

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.